Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00047450
Status:
COMPLETED
Last Update Posted:
2013-08-09
First Post:
2002-10-04
Brief Title:
Antidepressant Treatment in Older Adults With Schizophrenia
Sponsor:
Veterans Medical Research Foundation
Organization:
Veterans Medical Research Foundation
Study Overview
Official Title:
Citalopram Augmentation in Older Patients With Schizophrenia
Status:
COMPLETED
Status Verified Date:
2013-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and effectiveness of citalopram Celexa for the treatment of depressive symptoms in middle-aged and elderly patients with schizophrenia
Detailed Description:
Older people with schizophrenia suffer from greater physical comorbidity cognitive impairment and medication side effects compared to their younger counterparts Unfortunately little research is available to guide the treatment of subsyndromal depressive symptoms in older adults This study will compare the antidepressant citalopram to placebo to determine the most effective treatment for reducing depressive symptoms in older patients with schizophrenia
After patients have been on stable treatment with antipsychotic medication for at least 4 weeks they are randomly assigned to receive antipsychotic medication plus either citalopram or placebo for 3 months Depressive symptoms and side effects are assessed weekly for the first month biweekly for the second month and again at the end of the third month Cognition motor and daily functioning quality of life and medication adherence are assessed throughout the study
After patients have been on stable treatment with antipsychotic medication for at least 4 weeks they are randomly assigned to receive antipsychotic medication plus either citalopram or placebo for 3 months Depressive symptoms and side effects are assessed weekly for the first month biweekly for the second month and again at the end of the third month Cognition motor and daily functioning quality of life and medication adherence are assessed throughout the study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| DATR A4-GPX | US NIH GrantContract | None | httpsreporternihgovquickSearchR01MH063931 |
| R01MH063931 | NIH | None | None |